{
  "api": "assay-systems/v1",
  "key_tier": "none",
  "retrieved": "2026-10-16T14:04:05Z",
  "source": "Assay Systems register, https://assay-systems.com/register/",
  "access_notice": "On 15 November 2026, automated access to assay-systems.com closes. After that date, access is available only under a paid annual subscription contract. Contact: contact@assay-systems.com",
  "data": {
    "id": "ASY-CA-1SEJY4R1YX",
    "type": "grant",
    "country": "ca",
    "name": "SUSSEX RESEARCH LABORATORIES INC.: federal grants and contributions",
    "url": "https://assay-systems.com/register/ca/grants/r/sussex-research-laboratories-inc/",
    "summary": "8 federal grant and contribution agreements worth $1.3M with SUSSEX RESEARCH LABORATORIES INC., 2009–2026.",
    "figures": [
      {
        "label": "agreements",
        "value": 8,
        "unit": "count"
      },
      {
        "label": "value",
        "value": 1300000,
        "unit": "money",
        "currency": "CAD",
        "approximate": true,
        "display": "$1.3M"
      },
      {
        "label": "departments",
        "value": 2,
        "unit": "count"
      },
      {
        "label": "programs",
        "value": 4,
        "unit": "count"
      }
    ],
    "text": [
      "This project will develop an innovative platform for delivering mRNA therapies with enhanced precision to specific cells. It moves beyond traditional delivery methods by incorporating glycan-based targeting ligands, which offer a new active targeting approach. This strategy has broad therapeutic applications, with the potential to greatly improve treatment outcomes.",
      "For pathogens such as the SARS-CoV-2 virus that are spread through inhalation, the cells of the lung are the first line of defense for the host. A detailed understanding of the temporal and structural components of these interactions may be used to augment the host’s immune protection system. These components include the glycans and their receptors on both the host and the viral surface. It is anticipated that unravelling the interactions of the host’s glycans with viral receptors will allow for the development of practical diagnostic and therapeutic modalities. The SARS-CoV-2 virus utilizes i",
      "Develop digital adoption plan",
      "Participation in the Canadian medical biotechnology co-innovation mission to the Eureka Global Innovation Summit and Swiss Biotech Day in Switzerland – May 3 to 8, 2026. Delegation led by the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop international partnerships and potential project ideas under the Eureka Programs."
    ],
    "records": [
      {
        "name": "grants and contributions register",
        "url": "https://assay-systems.com/register/ca/grants/"
      },
      {
        "name": "Ottawa–Vanier",
        "url": "https://assay-systems.com/register/ca/grants/riding/35078-ottawa-vanier/"
      },
      {
        "name": "National Research Council Canada",
        "url": "https://assay-systems.com/register/ca/grants/department/national-research-council-canada/"
      },
      {
        "name": "Innovation, Science and Economic Development Canada",
        "url": "https://assay-systems.com/register/ca/grants/department/innovation-science-and-economic-development-canada/"
      }
    ],
    "assay_record": "ASY-CA-1SEJY4R1YX",
    "cite_as": "Assay Systems, \"SUSSEX RESEARCH LABORATORIES INC.: federal grants and contributions\", https://assay-systems.com/register/ca/grants/r/sussex-research-laboratories-inc/"
  }
}